PTPRC and neoplasm: Using a myeloid immunoprofiling panel with a sequential gating strategy (Supplementary Fig. 7a), we validated the accumulation of tumor-infiltrating CD45+Lin−CD11b+ Ly-6G−Ly-6C+F4/80+ macrophages in PRL3-zumab-treated tumors (Supplementary Fig. 7b, c).